<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>0864-084X</journal-id>
<journal-title><![CDATA[Nucleus]]></journal-title>
<abbrev-journal-title><![CDATA[Nucleus]]></abbrev-journal-title>
<issn>0864-084X</issn>
<publisher>
<publisher-name><![CDATA[CUBAENERGIA]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S0864-084X2019000100001</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Estimación de las desviaciones volumétricas de dosis entregada vs. planificada durante el tratamiento de hipertiroidismo con 131I: resultados preliminares]]></article-title>
<article-title xml:lang="en"><![CDATA[Estimation of volumetric dose distribution delivery deviations vs. dose planned in 131I hyperthyroidism treatment: preliminary results]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[López Díaz]]></surname>
<given-names><![CDATA[Adlin]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Martín]]></surname>
<given-names><![CDATA[Juan Miguel]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Fernández]]></surname>
<given-names><![CDATA[Viviana]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Pérez]]></surname>
<given-names><![CDATA[Amalia]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Ramos Rodríguez]]></surname>
<given-names><![CDATA[Eduardo O.]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Hospital Hermanos Ameijeiras (HHA) Departamento de Medicina Nuclear ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>Cuba</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Universidad Nacional de San Martín (UNSAM)  ]]></institution>
<addr-line><![CDATA[Buenos Aires ]]></addr-line>
<country>Argentina</country>
</aff>
<aff id="Af3">
<institution><![CDATA[,Instituto Superior de Tecnologías y Ciencias Aplicadas (InsTEC) Facultad de Ciencias y Tecnologías Nucleares ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>Cuba</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>06</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>06</month>
<year>2019</year>
</pub-date>
<numero>65</numero>
<fpage>1</fpage>
<lpage>5</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_arttext&amp;pid=S0864-084X2019000100001&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_abstract&amp;pid=S0864-084X2019000100001&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_pdf&amp;pid=S0864-084X2019000100001&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen En 2013, la Asociación Europea de Medicina Nuclear (AEMN) recomendó un &#8220;Procedimiento estándar&#8221; para desarrollar la dosimetría individual pretratamiento del Hipertiroidismo con 131I basada en la captación y en cinética tiroidea del paciente. Para estimar las desviaciones en la distribución de dosis entregada vs planificada al volumen tiroideo bajo este procedimiento, se desarrolló y verificó una aplicación en Matlab. Esta aplicación desarrolla el ajuste de la farmacocinética tiroidea, los cálculos de actividad acumulada, la estimación de la masa funcional tiroidea, el cálculo de la actividad a administrar para garantizar la dosis prescrita por el médico, y estimar el mapa tridimensional (3D) de dosis y los parámetros estadísticos relacionados que la caracterizan. La aplicación desarrollada se verificó empleando una imagen-maniquí y 6 farmacocinéticas conocidas. Además, se estimaron y verificaron los parámetros dosimétricos de planificación en 6 pacientes con dosis prescritas entre 150-400 Gy (promedio 241,67 Gy). Las distribuciones de actividad acumulada y de dosis absorbida fueron marcadamente heterogéneas. La distribución de dosis 3D mostró desviaciones estándar entre 18,01-27,08 % de la dosis prescrita. Las diferencias entre la dosis máxima y mínima por voxel/MBq de actividad administrada fue de 74-129 %. De acuerdo a los resultados, sólo entre el 50,2 % y 71,4 % de volumen tiroideo se tratará con la dosis prescrita ±20 %. Conclusiones: la dosis administrada al tejido tiroideo es no-homogénea y discrepa significativamente de la prescrita en algunas regiones, situación que requiere estudios posteriores más profundos con el objetivo de optimizar el tratamiento y sus resultados.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract In 2013, the European Association of Nuclear Medicine Dosimetry Committee recommends a &#8220;Standard Operational Procedures for Hyperthyroidism Pre-Therapeutic Dosimetry&#8221; based on the assessment of the individual 131I uptake and kinetics. To estimate the 3D dose delivery deviations from prescribed dose during patient specific application of this SOP, a computer Matlab application was developed and verified. It was design to execute: radiopharmaceutical curve fitting, cumulated activity calculations, functional thyroid mass estimation, obtain the therapeutic planning activity to warranty the prescribed dose and produce the 3D planning dose map and related dosimetry parameters. 6 patients with 150-400Gy prescribed dose data planning (average 241,67Gy) were analysed using the developed application. The developed system was verify successfully using a test image phantom and 6 known pharmacokinetics data. The tridimensional thyroid volume cumulated activity and dose distributions were heterogeneous. 3D dose distribution showed standard deviations between 18.01-27.08 % of prescribed dose. The differences between maximum and minimum dose value per voxel/MBq were 74-129%. According to the result, between 50,2 % and 71,4 % of patient&#8217;s thyroid will be treat with a dose of DP±20 % of planned dose, the rest will be overdose or sub dose. Conclusions: the 3D treatment planning dose distribution were completely no-homogenous, the significant difference observed should be study in the future more deeply in order to optimized the hyperthyroidism iodine treatment.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[dosimetría]]></kwd>
<kwd lng="es"><![CDATA[hipertiroidismo]]></kwd>
<kwd lng="es"><![CDATA[yodo 131]]></kwd>
<kwd lng="es"><![CDATA[optimización]]></kwd>
<kwd lng="es"><![CDATA[pacientes]]></kwd>
<kwd lng="es"><![CDATA[terapia]]></kwd>
<kwd lng="es"><![CDATA[verificación]]></kwd>
<kwd lng="en"><![CDATA[dosimetry]]></kwd>
<kwd lng="en"><![CDATA[hyperthyroidism]]></kwd>
<kwd lng="en"><![CDATA[iodine 131]]></kwd>
<kwd lng="en"><![CDATA[optimization]]></kwd>
<kwd lng="en"><![CDATA[patients]]></kwd>
<kwd lng="en"><![CDATA[therapy]]></kwd>
<kwd lng="en"><![CDATA[verification]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>[1]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[ROOIJ]]></surname>
<given-names><![CDATA[AD]]></given-names>
</name>
<name>
<surname><![CDATA[VANDENBROUCKE]]></surname>
<given-names><![CDATA[JP]]></given-names>
</name>
<name>
<surname><![CDATA[SMIT]]></surname>
<given-names><![CDATA[JW]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Clinical outcomes after estimated versus calculated activity of radioiodine for the treatment of hyperthyroidism: systematic review and meta-analysis]]></article-title>
<source><![CDATA[Eur J End]]></source>
<year>2009</year>
<volume>161</volume>
<page-range>771-7</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>[2]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[HÄNSCHEID]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[LASSMANN]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[REINERS]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Dosimetry prior to I-131 therapy of benign thyroid disease]]></article-title>
<source><![CDATA[Z Med Phys]]></source>
<year>2011</year>
<volume>21</volume>
<page-range>250-7</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>[3]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[ISSELT]]></surname>
<given-names><![CDATA[JV]]></given-names>
</name>
<name>
<surname><![CDATA[KLERK]]></surname>
<given-names><![CDATA[JD]]></given-names>
</name>
<name>
<surname><![CDATA[LIPS]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Radioiodine treatment of hyperthyroidism: fixed or calculated doses; intelligent design or science?]]></article-title>
<source><![CDATA[Eur J Nucl Med Mol Imaging]]></source>
<year>2007</year>
<volume>34</volume>
<page-range>1883-34</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>[4]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[MERRILL]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[HOROWITZ]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[TRAINO]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Accuracy and optimal timing of activity measurements in estimating the absorbed dose of radioiodine in the treatment of Graves&#8217; disease]]></article-title>
<source><![CDATA[Phys Med Biol]]></source>
<year>2011</year>
<volume>56</volume>
<page-range>557-71</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>[5]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[HÄNSCHEID]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[CANZI]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[ESCHNER]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[EANM Dosimetry committee series on standard operational procedures for pre-therapeutic dosimetry II. Dosimetry prior to radioiodine therapy of benign thyroid diseases]]></article-title>
<source><![CDATA[Eur J Nucl Med Mol Imaging]]></source>
<year>2013</year>
</nlm-citation>
</ref>
<ref id="B6">
<label>[6]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[BOLCH]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[BOUCHET]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[ROBERTSON]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The dosimetry of nonuniform activity distributions-radionuclide S values at the voxel level. Medical Internal Radiation Dose Committee]]></article-title>
<source><![CDATA[J Nucl Med]]></source>
<year>1999</year>
<volume>40</volume>
<numero>17</numero>
<issue>17</issue>
<page-range>11S-36S</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>[7]</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[RAMOS RODRÍGUEZ]]></surname>
<given-names><![CDATA[EO]]></given-names>
</name>
</person-group>
<source><![CDATA[Implementación del método de los factores S para dosimetría 3D con 131I en el tratamiento del hipertiroidismo]]></source>
<year>2016</year>
<publisher-loc><![CDATA[La Habana ]]></publisher-loc>
<publisher-name><![CDATA[INSTEC]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B8">
<label>[8]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[PACILIO]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[AMATO]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[LANCONELLI]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[BASILE]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Differences in 3D dose distributions due to calculation method of voxel S-values and the influence of image blurring in SPECT]]></article-title>
<source><![CDATA[Phys Med Biol]]></source>
<year>2015</year>
<volume>60</volume>
<page-range>1945-64</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>[9]</label><nlm-citation citation-type="confpro">
<person-group person-group-type="author">
<name>
<surname><![CDATA[LÓPEZ]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[REYNOSA]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[PALAU]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[MARTÍN]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
</person-group>
<source><![CDATA[Methodology for gamma cameras calibration for I-131 uptake quantification in hyperthyroidism diseases]]></source>
<year>2015</year>
<conf-name><![CDATA[ XVWorkshop on Nuclear Physics and IX International Symposium on Nuclear and Related Techniques WONP-NURT'2015]]></conf-name>
<conf-loc> </conf-loc>
<publisher-loc><![CDATA[Havana, Cuba ]]></publisher-loc>
</nlm-citation>
</ref>
<ref id="B10">
<label>[10]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[MALAGO]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[D&#8217;ONOFRIO]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[FERDEGHINI]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[MANTOVANI]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Thyroid volumetric quantification comparative evaluation between conventional and volumetric ultrasonography]]></article-title>
<source><![CDATA[J Ultrasound Med]]></source>
<year>2008</year>
<volume>27</volume>
<page-range>1727-33</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>[11]</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[CUMALI]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[GOLDSMITH]]></surname>
<given-names><![CDATA[SJ]]></given-names>
</name>
</person-group>
<source><![CDATA[Nuclear medicine therapy principles and clinical applications]]></source>
<year>2013</year>
<publisher-loc><![CDATA[New York ]]></publisher-loc>
<publisher-name><![CDATA[Springer Science+Business]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B12">
<label>[12]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[DEWARAJA]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[FREY]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[SGOUROS]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[MIRD Pamphlet No. 23: Quantitative SPECT for patient-speci&#64257;c 3-dimensional dosimetry in internal radionuclide therapy]]></article-title>
<source><![CDATA[J Nucl Med]]></source>
<year>2012</year>
<volume>53</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>1310-25</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>[13]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[DEWARAJA]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[LJUNGBERG]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[GREEN]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[MIRD Pamphlet No. 24: Guidelines for quantitative 131I SPECT in dosimetry applications]]></article-title>
<source><![CDATA[J Nucl Med]]></source>
<year>2013</year>
<volume>54</volume>
<numero>12</numero>
<issue>12</issue>
<page-range>2182-8</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>[14]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[TORRES]]></surname>
<given-names><![CDATA[LA]]></given-names>
</name>
<name>
<surname><![CDATA[COCA]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[CORNEJO]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Radionuclide targeted theraphy: three-dimensional dose estimations for treatment planning]]></article-title>
<source><![CDATA[ALASBIMN journal]]></source>
<year>2011</year>
<volume>14</volume>
<numero>54</numero>
<issue>54</issue>
</nlm-citation>
</ref>
<ref id="B15">
<label>[15]</label><nlm-citation citation-type="book">
<source><![CDATA[IAEA. Quantitative nuclear medicine imaging: concepts, requirements and methods]]></source>
<year>2014</year>
<publisher-loc><![CDATA[Vienna ]]></publisher-loc>
<publisher-name><![CDATA[IAEA]]></publisher-name>
</nlm-citation>
</ref>
</ref-list>
</back>
</article>
